Core Insights - The article discusses the importance of the price-to-book (P/B) ratio as a tool for value investing, highlighting its utility in identifying undervalued stocks with strong growth potential [1][2]. Group 1: Understanding P/B Ratio - The P/B ratio is calculated by dividing the current stock price by the book value per share, indicating how much investors pay for each dollar of book value [2][6]. - A P/B ratio of less than one suggests that a stock is undervalued, while a ratio greater than one indicates overvaluation [6][7]. - The P/B ratio is particularly relevant for industries with tangible assets, such as finance and manufacturing, but may be misleading for companies with high R&D expenses or significant debt [9][10]. Group 2: Screening Criteria for Value Stocks - Stocks with a P/B ratio lower than the industry median are considered attractive, as they have room for price appreciation [12]. - Additional screening parameters include a lower price-to-sales (P/S) ratio than the industry median, a price-to-earnings (P/E) ratio below the industry average, and a PEG ratio of less than one, indicating undervaluation relative to growth prospects [13][14][15]. - Stocks must also have a minimum trading price of $5 and a substantial average trading volume to ensure liquidity [14][15]. Group 3: Selected Low P/B Stocks - StoneCo (STNE) offers financial technology solutions and has a projected 3-5 year EPS growth rate of 30.3%, with a Zacks Rank of 1 and a Value Score of B [16]. - PagSeguro Digital (PAGS) provides digital payment solutions and has a projected EPS growth rate of 14.2%, also holding a Zacks Rank of 1 and a Value Score of B [17]. - KT Corporation (KT) is a telecommunications provider with a projected EPS growth rate of 51.7% and a Zacks Rank of 2 with a Value Score of A [19]. - Arrow Electronics (ARW) is a major distributor of electronic components, with a projected EPS growth rate of 20.7% and a Zacks Rank of 2 with a Value Score of A [19]. - CVS Health has a projected EPS growth rate of 14.3% and holds a Zacks Rank of 2 with a Value Score of A [20].

Core Insights - CVS Pharmacy has completed the acquisition of select Rite Aid and Bartell Drugs assets, enhancing its pharmacy services in the Pacific Northwest and serving millions of customers [1][2]. Expansion across the Pacific Northwest - CVS now operates 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon, and Washington [2]. - The company has acquired prescription files from 626 former Rite Aid and Bartell Drugs pharmacies across 15 states, allowing CVS to serve over nine million patients [2]. Recruitment and Investment to Support Pharmacy Operations - CVS has hired more than 3,500 former employees from Rite Aid and Bartell Drugs to maintain service standards and ensure timely prescription support [4]. - Targeted investments have been made in existing pharmacy locations to improve staff scheduling, recruitment, and training [4]. Transaction Finalised Following Bankruptcy Court Approval - The acquisition was approved by the US Bankruptcy Court for the District of New Jersey in May 2025, and the entire transaction was completed in under four months [6]. - The final store acquisitions were concluded on September 30, with locations in Bend, Oregon, and Bainbridge Island, Washington [6]. Key Factors in Acquisition Decisions - CVS prioritized convenience and access to essential prescriptions when selecting Rite Aid locations and prescription files for acquisition [7]. - Most CVS stores receiving transferred prescription files are within three miles of existing Rite Aid branches, with nearly half within one mile, minimizing disruption for affected patients and communities [7].

Core Insights - CVS Health has completed the acquisition of 63 Rite Aid stores in Idaho, Oregon, and Washington, along with prescription files across 15 states, serving over 9 million customers [2][3] - The acquisition follows Rite Aid's bankruptcy filing earlier this year, marking its second bankruptcy in less than two years [3] - By acquiring prescription files, CVS and other pharmacy chains avoided taking on additional debt from physical store locations during the bankruptcy proceedings [4] Company Operations - CVS is now operating 63 former Rite Aid and Bartell Drugs locations and has acquired prescription files from 626 former Rite Aid and Bartell Drugs pharmacies across 15 states [5] - The company has hired over 3,500 former Rite Aid and Bartell Drug employees as part of the acquisition and store conversions [5] Strategic Goals - CVS Health aims to expand access to pharmacy care and grow its retail footprint in local communities through this acquisition [6] - The company plans to leverage its innovative pharmacy care programs and exclusive store brand products to enhance customer experience for former Rite Aid and Bartell Drugs patients [6]

Core Insights - CVS Health has shown strong stock performance, with an 8.4% increase over the past month and a 77.5% gain since the start of the year, outperforming the Zacks Medical sector and the Zacks Medical Services industry [1][2] Financial Performance - CVS Health reported an EPS of $1.81 in its last earnings report, exceeding the consensus estimate of $1.47, and beat the revenue estimate by 5.54% [2] - For the current fiscal year, CVS Health is expected to post earnings of $6.36 per share on revenues of $392.28 billion, reflecting a 17.34% change in EPS and a 5.22% change in revenues [3] - For the next fiscal year, the company is projected to earn $7.16 per share on revenues of $415.1 billion, indicating a year-over-year change of 12.47% in EPS and 5.82% in revenues [3] Valuation Metrics - CVS Health has a Value Score of A, with Growth and Momentum Scores of C, resulting in a VGM Score of A [6] - The stock trades at 12.5X current fiscal year EPS estimates, below the peer industry average of 17.1X, and at 8.8X trailing cash flow compared to the peer group's average of 10.5X [7] - The PEG ratio stands at 0.88, positioning CVS Health favorably among value investors [7] Zacks Rank - CVS Health holds a Zacks Rank of 2 (Buy), supported by a solid earnings estimate revision trend [8] - The stock aligns with the recommendation for investors to select stocks with Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, indicating potential for future growth [8] Industry Comparison - Labcorp Holdings Inc. is a notable peer with a Zacks Rank of 2 (Buy) and solid financial performance, expected to post earnings of $16.30 per share on revenue of $14 billion for the current fiscal year [9][10] - The Medical Services industry is performing well, ranking in the top 39% of all industries, suggesting favorable conditions for both CVS Health and Labcorp Holdings Inc. [11]

Key Points CVS Health's shares have climbed sharply this year, largely due to much-improved results. The company is still dealing with some headwinds, but it has a plan to address them. CVS Health's diversified healthcare ecosystem helps to make the stock attractive. 10 stocks we like better than CVS Health › Despite significant market volatility and looming economic troubles, it's been an excellent year for CVS Health (NYSE: CVS): Shares of the pharmacy giant have soared by 76% since early Janua ...

Group 1 - Morgan Stanley analyst Erin Wright raised the price target on CVS Health (CVS) to $89 from $82, maintaining an Overweight rating on the shares [1] - Last week's Stars results were described as "encouraging" for the sector, indicating a positive sentiment shift [1] - Managed Care Organization sentiment has "improved slightly," but there remains a need for further validation as focus shifts to utilization and early insights on 2026 [1]

We recently published Jim Cramer Discussed These 11 Stocks & The Market’s 3rd Bull Run Anniversary. CVS Health Corporation (NYSE:CVS) is one of the stocks Jim Cramer recently discussed. CVS Health Corporation (NYSE:CVS) is one of the largest healthcare services and pharmacy companies in the US. The firm scored a major win last week when 81% of users of its Aetna service rated it four stars or higher. The data saw CVS Health Corporation (NYSE:CVS) pull ahead of major rivals such as UnitedHealth and Humana. ...

Key Takeaways CVS' Aetna secured top-tier 2026 Medicare ratings, with 81% of members in 4-star or higher plans.CVS shares jumped 1.6% post-announcement, extending a 73.5% year-to-date rally.Aetna's 2026 MA plans expand to 43 states, offering $0 premiums and broad benefit access.On Thursday, the Centers for Medicare & Medicaid Services (“CMS”) released the 2026 Star Ratings for Medicare Advantage Prescription Drug (“MAPD”) plans. The five-star rating system evaluates Medicare health care and drug plans to en ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - CVS Health's Aetna insurance business has achieved a significant milestone with over 81% of its members in Medicare Advantage plans rated 4 stars or higher for 2026 [1] Group 1 - Aetna's performance in Medicare Advantage plans indicates a strong quality rating, which may enhance its competitive position in the healthcare market [1] - The high percentage of members in well-rated plans suggests a focus on quality care and customer satisfaction within Aetna's offerings [1]